INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76801, 'Deferasirox', 'Cyclosporine', 'Major', 'Theoretical concerns exist regarding the potential for increased risk of renal impairment during coadministration of deferasirox with other nephrotoxic agents. The use of deferasirox has been associated with postmarketing reports of acute renal failure, in some cases resulting in dialysis or even fatality.', 'DDInter', 'Caution is advised if deferasirox is used in combination with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Serum creatinine and/or creatinine clearance should be closely monitored (e.g., prior to initiation of deferasirox therapy, then weekly during the first month after initiation or modification of therapy and monthly thereafter), especially in the elderly and patients with preexisting renal impairment, comorbid conditions, dehydration, or severe infections. Dosage reduction, interruption, or discontinuation should be considered in the presence of creatinine elevations. A progressive increase in serum creatinine beyond the age-appropriate upper limit of normal may warrant an interruption of therapy. Once the creatinine has returned to within the normal range, therapy may be reinitiated at a lower dose followed by a gradual dose escalation according to the product labeling, provided the clinical benefit is expected to outweigh potential risks.', 'Synergism', 'Caution is advised if deferasirox is used in combination with other potentially nephrotoxic agents (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76902/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Lanthanum carbonate, Difelikefalin, Levoleucovorin, Arginine, Methionine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76802, 'Deflazacort', 'Cyclosporine', 'Moderate', 'Coadministration of cyclosporine with a corticosteroid may result in altered (usually elevated) plasma concentrations of one or both drugs. Cyclosporine and corticosteroids undergo metabolism primarily by CYP450 3A4, thus competitive inhibition of metabolic clearance may occur during concomitant use.', 'DDInter', 'Caution is advised during concomitant therapy with cyclosporine and corticosteroids. Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever one or the other agent is added to or withdrawn from therapy in patients stabilized on their existing therapeutic regimen, and the dosage(s) adjusted as necessary.', 'Metabolism', 'Caution is advised during concomitant therapy with cyclosporine and corticosteroids.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76903/', '', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76803, 'Dehydrocholic acid', 'Cyclosporine', 'Minor', 'Bile acid salts may increase the bioavailability of oral cyclosporine. Data have been conflicting. The mechanism and clinical significance are unknown. No action is necessary; however, clinicians should be aware of the possibility of an interaction.', 'DDInter', '-', 'Absorption', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76904/', '', 'Golimumab, Antithymocyte immunoglobulin (rabbit), Ravulizumab, Diroximel fumarate, Methotrexate, Inebilizumab, Belumosudil, Ozanimod, Emapalumab, Natalizumab, Fingolimod, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76804, 'Delavirdine', 'Cyclosporine', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the blood concentrations of cyclosporine, which is primarily metabolized by the isoenzyme. The risk of nephro- and neurotoxicity associated with cyclosporine may be increased.', 'DDInter', 'Caution is advised if cyclosporine is used with potent inhibitors of CYP450 3A4. Cyclosporine blood levels and renal function should be checked frequently and the dosage adjusted accordingly, particularly following initiation or discontinuation of macrolide therapy in patients who are stabilized on their cyclosporine regimen. Patients should be advised to notify their doctor if they experience possible signs of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions. Alternative treatment that do not interfere with cyclosporine metabolism should be considered whenever possible.', 'Metabolism', 'Caution is advised if cyclosporine is used with potent inhibitors of CYP450 3A4.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76905/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 'Cabotegravir, Zanamivir, Velpatasvir, Stavudine, Elbasvir, Tecovirimat, Pibrentasvir, Rimantadine, Elvitegravir, Peramivir, Emtricitabine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76805, 'Denosumab', 'Cyclosporine', 'Moderate', 'Concomitant use of immunosuppressive or myelosuppressive agents with denosumab may increase the risk of serious infections. Denosumab binds to and inhibits the receptor activator of nuclear factor kappa-B ligand (RANKL), which is expressed on activated T and B lymphocytes and in lymph nodes. Thus, denosumab alone may increase the risk of infections.', 'DDInter', 'Caution is advised if denosumab must be used in combination with immuno- or myelosuppressive agents. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. The need for continued denosumab therapy should be assessed when serious infections occur during treatment.', 'Synergism', 'Caution is advised if denosumab must be used in combination with immuno- or myelosuppressive agents.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76906/', '', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Voclosporin, Pegcetacoplan, Eculizumab, Sutimlimab, Alteplase, More', 'Tiludronic acid, Vosoritide, Cholecalciferol, Burosumab, Romosozumab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76806, 'Dexlansoprazole', 'Cyclosporine', 'Moderate', 'Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that can cause magnesium loss. Serious adverse events include tetany, seizures, tremor, carpopedal spasm, atrial fibrillation, supraventricular tachycardia, and abnormal QT interval; however, patients do not always exhibit these symptoms. Hypomagnesemia can also cause impaired parathyroid hormone secretion, which may lead to hypocalcemia. In approximately 25% of the cases of PPI-associated hypomagnesemia reviewed by the FDA, the condition did not resolve with magnesium supplementation alone but also required discontinuation of the PPI.', 'DDInter', 'Monitoring of serum magnesium levels is recommended prior to initiation of therapy and periodically thereafter if prolonged treatment with a proton pump inhibitor is anticipated or when combined with other agents that can cause hypomagnesemia such as diuretics, aminoglycosides, cation exchange resins, amphotericin B, cetuximab, cisplatin, cyclosporine, foscarnet, panitumumab, pentamidine, and tacrolimus. Patients should be advised to seek immediate medical attention if they develop potential signs and symptoms of hypomagnesemia such as palpitations, arrhythmia, muscle spasm, tremor, or convulsions. In children, abnormal heart rates may cause fatigue, upset stomach, dizziness, and lightheadedness. Magnesium replacement as well as discontinuation of the PPI may be required in some patients.', 'Synergism', 'Monitoring of serum magnesium levels is recommended prior to initiation of therapy and periodically thereafter if prolonged treatment with a proton pump inhibitor is anticipated or when combined with other agents that can cause hypomagnesemia such as diuretics, aminoglycosides, cation exchange resins, amphotericin B, cetuximab, cisplatin, cyclosporine, foscarnet, panitumumab, pentamidine, and tacrolimus.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76907/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Vonoprazan, Bismuth subcitrate potassium, Levofloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76807, 'Diatrizoate', 'Cyclosporine', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', 'DDInter', 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76908/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76808, 'Dicoumarol', 'Cyclosporine', 'Moderate', 'A few case reports have suggested that the concomitant use of cyclosporine and warfarin may result in both increased and reduced effects of both agents, although this interaction is not well established. The mechanism is unknown. A similar reaction may occur with other oral coumarin anticoagulants.', 'DDInter', 'It may be advisable to monitor prothrombin time (PT) and/or International Normalized Ratio(INR), as well as cyclosporine blood concentrations and the patient''s response is recommended if these agents are used together.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76909/', '', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Upadacitinib, Siponimod, Apremilast, More', 'Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, Streptokinase, Tinzaparin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76809, 'Diflunisal', 'Cyclosporine', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the nephrotoxic effects of cyclosporine, especially if dehydration is present. The exact mechanism is unknown but is apparently unrelated to plasma cyclosporine levels. The interaction has been reported with diclofenac and sulindac.', 'DDInter', 'Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76910/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Ziconotide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76810, 'Digoxin', 'Cyclosporine', 'Moderate', 'Cyclosporine may increase both serum levels and pharmacologic effects of digoxin. The mechanism is unknown, but may be related to inhibition of P-glycoprotein-mediated renal tubular secretion by cyclosporine.', 'DDInter', 'If these drugs must be used together, the patient should be closely monitored for evidence of digoxin toxicity. The need to readjust digoxin dosage after cardiac transplantation should be expected. Patients should be advised to notify their physicians if they experience signs of possible digoxin toxicity or electrolyte disturbances, such as weakness, lethargy, muscle pains or cramps, nausea, anorexia, visual changes, or irregular heartbeats.', 'Excretion', 'If these drugs must be used together, the patient should be closely monitored for evidence of digoxin toxicity.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76911/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Digitoxin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76811, 'Dihydroergotamine', 'Cyclosporine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors.', 'DDInter', 'Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors. Patients should be monitored for potential ergot toxicity including peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension.', 'Metabolism', 'Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76912/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Frovatriptan, Eptinezumab, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Erenumab, Almotriptan, Fremanezumab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76812, 'Dimethyl fumarate', 'Cyclosporine', 'Moderate', 'The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may increase the risk of infections.', 'DDInter', 'The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated. Until further information is available, concomitant use should be avoided if possible.', 'Synergism', 'The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76913/', '', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Dimethyl fumarate, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Alteplase, Ascorbic acid, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76813, 'Diroximel fumarate', 'Cyclosporine', 'Moderate', 'The use of monomethyl fumarate (MMF) or its prodrugs, dimethyl fumarate and diroximel fumarate, with other immunosuppressive or myelosuppressive agents may increase the risk of infections.', 'DDInter', 'The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated. Until further information is available, concomitant use should be avoided if possible.', 'Synergism', 'The safety and efficacy of monomethyl fumarate, dimethyl fumarate, or diroximel fumarate in combination with other immunosuppressive or myelosuppressive agents have not been evaluated.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76914/', '', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Ravulizumab, Pegcetacoplan, Eculizumab, Diroximel fumarate, Sutimlimab, Alteplase, Ascorbic acid, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76814, 'Disopyramide', 'Cyclosporine', 'Moderate', 'The concomitant use of disopyramide with cyclosporine or theophylline may theoretically result in increased serum concentrations of both drugs. The proposed mechanism is competitive inhibition of CYP450 3A4 metabolism.', 'DDInter', 'Clinical and laboratory monitoring for altered efficacy and safety of both drugs is recommended during concomitant therapy.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76915/', '', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Upadacitinib, Apremilast, Inebilizumab, Cladribine, More', 'Tocainide, Procainamide, Mexiletine, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76815, 'Docetaxel', 'Cyclosporine', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 or dual CYP450 3A4 and P-glycoprotein (P-gp) inhibitors may significantly increase the plasma concentrations of docetaxel, which is a substrate of both CYP450 3A4 and P-gp.', 'DDInter', 'Concomitant use of docetaxel with CYP450 3A4 inhibitors, particularly potent inhibitors or dual CYP450 3A4 and P-gp inhibitors such as itraconazole, ketoconazole, posaconazole, conivaptan, ceritinib, idelalisib, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics, should generally be avoided. Some authorities recommend avoiding concomitant use of docetaxel during and for 2 weeks after treatment with itraconazole. If concomitant use is required, a reduced dosage of docetaxel should be considered. Based on extrapolation from the pharmacokinetic study in 7 cancer patients, a 50% reduction in the docetaxel dose may be reasonable. Patients should be closely monitored for the development of docetaxel toxicity such as myelosuppression, stomatitis, neurotoxicity (e.g., paraesthesia, dysesthesia, pain), myalgia, asthenia, fluid retention, nausea, vomiting, and diarrhea.', 'Metabolism', 'Concomitant use of docetaxel with CYP450 3A4 inhibitors, particularly potent inhibitors or dual CYP450 3A4 and P-gp inhibitors such as itraconazole, ketoconazole, posaconazole, conivaptan, ceritinib, idelalisib, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics, should generally be avoided.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76916/', '', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More', 'Topotecan, Teniposide, Vinorelbine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76816, 'Dofetilide', 'Cyclosporine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of dofetilide, which is partially metabolized by the isoenzyme. The use of dofetilide has been associated with dose-related prolongation of the QT interval, thus elevated plasma levels of the drug may potentiate the risk of ventricular arrhythmias such as ventricular tachycardia and torsade de pointes as well as cardiac arrest and sudden death.', 'DDInter', 'Close clinical and laboratory monitoring is recommended whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage of dofetilide adjusted accordingly as necessary. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Metabolism', 'Close clinical and laboratory monitoring is recommended whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage of dofetilide adjusted accordingly as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76917/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 'Tocainide, Procainamide, Mexiletine, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76817, 'Donepezil', 'Cyclosporine', 'Minor', 'Coadministration with inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations of donepezil, which is primarily metabolized by these isoenzymes.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76918/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Rivastigmine, Galantamine, Tacrine, Memantine, Ginkgo biloba, Aducanumab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76818, 'Doravirine', 'Cyclosporine', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of doravirine, which is primarily metabolized by the isoenzyme.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76919/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 'Cabotegravir, Zanamivir, Velpatasvir, Stavudine, Elbasvir, Tecovirimat, Pibrentasvir, Rimantadine, Elvitegravir, Peramivir, Emtricitabine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76819, 'Doxacurium', 'Cyclosporine', 'Moderate', 'Cyclosporine may enhance and prolong the neuromuscular blockade of the nondepolarizing skeletal muscle relaxants. The mechanism is unknown.', 'DDInter', 'Patients should be monitored for excessive and/or prolonged neuromuscular blockade.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76920/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 'Botulinum toxin type A', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76820, 'Doxorubicin', 'Cyclosporine', 'Moderate', 'Cyclosporine can significantly decrease plasma clearance both of doxorubicin and of its main metabolite, doxorubicinol. In resistant cells, intracellular accumulation of doxorubicin does not occur because the multidrug resistance-1 (MDR-1) gene product, a membrane glycoprotein, is an energy-dependent efflux pump. Cyclosporine blocks the function of this pump, allowing a greater intracellular accumulation of some cytotoxic agents.', 'DDInter', 'This interaction may be used to clinical advantage in the treatment of cancer. If cyclosporine is used to decrease tumor cell resistance to doxorubicin, it is recommended that doxorubicin dosage be reduced to approximately 50% to 60% of the normally recommended dosage.', 'Others', 'This interaction may be used to clinical advantage in the treatment of cancer.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76921/', '', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', 'Valrubicin, Plicamycin, Bleomycin, Mitomycin, Epirubicin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76821, 'Dronedarone', 'Cyclosporine', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of dronedarone, which is primarily metabolized by the isoenzyme. Because dronedarone is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.', 'DDInter', 'The use of dronedarone in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, voriconazole, nefazodone, cyclosporine, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics is considered contraindicated. Patients currently receiving these agents should stop taking them before starting treatment with dronedarone. Some authorities consider concomitant administration of dronedarone and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.', 'Metabolism', 'The use of dronedarone in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, voriconazole, nefazodone, cyclosporine, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics is considered contraindicated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76922/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Tocainide, Procainamide, Mexiletine, Bretylium, Moricizine, Ibutilide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76822, 'Drospirenone', 'Cyclosporine', 'Moderate', 'The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim. Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.', 'DDInter', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Synergism', 'Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76923/', '', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, More', 'Estetrol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76823, 'Dupilumab', 'Cyclosporine', 'Moderate', 'Dupilumab, an interleukin-4 (IL-4) receptor antagonist, may alter the formation of CYP450 enzymes, which could lead to altered metabolism of CYP450 substrates. CYP450 enzyme formation can be altered by increased cytokines during chronic inflammation.', 'DDInter', 'Consider monitoring pharmacologic response and/or therapeutic concentration of CYP450 substrates, especially those with a narrow therapeutic index, more closely whenever dupilumab is added to or withdrawn from therapy, and consider adjusting the dose of the CYP450 substrate as necessary.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76924/', '', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, Apremilast, Inebilizumab, More', 'Deoxycholic acid, Calcium gluconate, Pimecrolimus, Magnesium sulfate, Glycopyrronium, Aminobenzoic acid, Ivermectin, Caffeine, Cromoglicic acid, Povidone-iodine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76824, 'Dutasteride', 'Cyclosporine', 'Moderate', 'Based on in vitro data, coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of dutasteride, which is metabolized by the isoenzyme.', 'DDInter', 'The possibility of prolonged and/or increased pharmacologic effects of dutasteride should be considered during concomitant therapy with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.', 'Metabolism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76925/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76825, 'Duvelisib', 'Cyclosporine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of duvelisib, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Caution is advised when duvelisib is used with CYP450 3A4 inhibitors. Patients should be monitored for the development of toxicities such as diarrhea, colitis, neutropenia, thrombocytopenia, pneumonitis, infections, cutaneous reactions and hepatotoxicity, and the dosing adjusted or discontinued in accordance with the duvelisib product labeling.', 'Metabolism', 'Caution is advised when duvelisib is used with CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76926/', '', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More', 'Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76826, 'Echinacea', 'Cyclosporine', 'Minor', 'Theoretically, agents that are thought to have immunostimulant properties such as echinacea, vitamin E, cat''s claw, and zinc may antagonize the pharmacologic effects of immunosuppressants.', 'DDInter', '-', 'Antagonism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76927/', '', 'Methotrexate, Alemtuzumab, Pegcetacoplan, Cladribine, Belumosudil, Ozanimod, Teprotumumab, Thalidomide, Emapalumab, Ofatumumab, Baricitinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76827, 'Edoxaban', 'Cyclosporine', 'Major', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of edoxaban, which is a substrate of the efflux transporter.', 'DDInter', 'When used for the treatment of deep vein thrombosis and pulmonary embolism, the manufacturer recommends that edoxaban dosage be reduced to 30 mg once daily in patients receiving concomitant treatment with certain P-gp inhibitors including azithromycin, clarithromycin, erythromycin, oral itraconazole, oral ketoconazole, quinidine, and verapamil. This dosage recommendation is based on data from a clinical study, the Hokusai VTE study, and is limited to use with the specific P-gp inhibitors mentioned.', 'Absorption', 'When used for the treatment of deep vein thrombosis and pulmonary embolism, the manufacturer recommends that edoxaban dosage be reduced to 30 mg once daily in patients receiving concomitant treatment with certain P-gp inhibitors including azithromycin, clarithromycin, erythromycin, oral itraconazole, oral ketoconazole, quinidine, and verapamil.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76928/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 'Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, Streptokinase, Tinzaparin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76828, 'Efalizumab', 'Cyclosporine', 'Moderate', 'The use of efalizumab with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Efalizumab alone can cause serious infections requiring hospitalization, and the risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.', 'DDInter', 'The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated. Patients receiving other immunosuppressive agents should not be treated with efalizumab because of the possibility of excessive immunosuppression. The duration of the period following treatment with efalizumab before one should consider starting other immunosuppressive therapy has not been evaluated.', 'Synergism', 'The safety and efficacy of efalizumab in combination with other immunosuppressive agents or phototherapy have not been evaluated.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76929/', '', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Efalizumab, Alteplase, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76829, 'Efavirenz', 'Cyclosporine', 'Moderate', 'Coadministration with efavirenz may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is accelerated clearance due to induction of CYP450 3A4 activity by efavirenz.', 'DDInter', 'Caution is advised if efavirenz must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever efavirenz is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if efavirenz must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76930/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Anakinra, Inebilizumab, More', 'Cabotegravir, Zanamivir, Velpatasvir, Stavudine, Elbasvir, Tecovirimat, Pibrentasvir, Rimantadine, Elvitegravir, Peramivir, Emtricitabine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76830, 'Elagolix', 'Cyclosporine', 'Major', 'Coadministration with potent inhibitors of organic anion transporting polypeptide (OATP) 1B1 may significantly increase the plasma concentrations of elagolix, which is a substrate of the hepatic uptake transporter.', 'DDInter', 'Concomitant use of elagolix with potent OATP 1B1 inhibitors is considered contraindicated.', 'Distribution', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76931/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Ganirelix, Cetrorelix, Nafarelin, Gonadorelin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76831, 'Eletriptan', 'Cyclosporine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of eletriptan, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Eletriptan should not be used within at least 72 hours of treatment with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, nefazodone, delavirdine, most protease inhibitors, and ketolide and certain macrolide antibiotics. Patients should have vital signs monitored regularly and advised to notify their physician if they experience signs and symptoms of vasospasm such as numbness, tingling, or cyanosis in the extremities; muscle pains; weakness; or chest pain or tightness. Alternatively, other 5-HT1 receptor agonists that are not metabolized by CYP450 3A4 may be considered, such as frovatriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan.', 'Metabolism', 'Eletriptan should not be used within at least 72 hours of treatment with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, nefazodone, delavirdine, most protease inhibitors, and ketolide and certain macrolide antibiotics.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76932/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 'Frovatriptan, Eptinezumab, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Erenumab, Almotriptan, Fremanezumab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76832, 'Eliglustat', 'Cyclosporine', 'Moderate', 'Coadministration with weak inhibitors of CYP450 3A4 may increase the plasma concentrations of eliglustat, which is primarily metabolized by CYP450 2D6 and, to a lesser extent, CYP450 3A4. Eliglustat at substantially elevated plasma concentrations is predicted to cause prolongation of the PR, QTc and QRS cardiac intervals, which may increase the risk of bradycardia, atrioventricular block, cardiac arrest, and serious ventricular arrhythmias such as torsade de pointes.', 'DDInter', 'Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers. No dosage adjustment for eliglustat is necessary when used with weak CYP450 3A4 inhibitors in extensive or intermediate metabolizers.', 'Metabolism', 'Concomitant use of eliglustat with weak CYP450 3A4 inhibitors such as chloramphenicol, cyclosporine, danazol, dasatinib, ethinyl estradiol, fluvoxamine, goldenseal, isoniazid, ivacaftor, lapatinib, lomitapide, nifedipine, nilotinib, palbociclib, pazopanib, suvorexant, ticagrelor, and zafirlukast is not recommended in CYP450 2D6 poor metabolizers.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76933/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 'Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Levocarnitine, Laronidase, Imiglucerase, Phenylbutyric acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76833, 'Eltrombopag', 'Cyclosporine', 'Moderate', 'Coadministration with cyclosporine may decrease eltrombopag exposure. The mechanism is unknown. Eltrombopag is an in vitro substrate and inhibitor of the breast cancer resistance protein (BCRP) efflux transporter, and cyclosporine also inhibits BCRP.', 'DDInter', 'It is generally recommended that the patient''s platelet count be monitored at least weekly for 2 to 3 weeks when eltrombopag is coadministered with cyclosporine, and the eltrombopag dose adjusted as necessary.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76934/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More', 'Romiplostim, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Coagulation Factor IX Human', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76834, 'Eluxadoline', 'Cyclosporine', 'Major', 'Coadministration with inhibitors of organic anion transporting polypeptide (OATP) 1B1 may significantly increase the plasma concentrations of eluxadoline. Based on available data, inhibition of OATP1B1-mediated hepatic uptake appears to reduce both the hepatic first-pass extraction and systemic biliary clearance of eluxadoline.', 'DDInter', 'The recommended dosage of eluxadoline is 75 mg twice daily when used with OATP1B1 inhibitors. Patients should be monitored for adverse effects such as sedation, nausea, vomiting, constipation, abdominal pain, liver enzyme elevations, and pancreatitis.', 'Metabolism', 'The recommended dosage of eluxadoline is 75 mg twice daily when used with OATP1B1 inhibitors.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76935/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Opium, Diphenoxylate, Difenoxin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76835, 'Enalapril', 'Cyclosporine', 'Moderate', 'Coadministration of cyclosporine with ACE inhibitors or angiotensin II receptor antagonists may increase the risk of hyperkalemia or precipitate acute renal failure. Cyclosporine causes afferent arteriolar vasoconstriction and decreased glomerular filtration. These effects may be significant when combined with ACE inhibitors or angiotensin II receptor antagonists, which block the mechanism that maintains glomerular filtration rate by constricting the efferent arterioles.', 'DDInter', 'Serum potassium levels and renal function should be checked regularly when cyclosporine is used in combination with ACE inhibitors or angiotensin II receptor antagonists. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Excretion', 'Serum potassium levels and renal function should be checked regularly when cyclosporine is used in combination with ACE inhibitors or angiotensin II receptor antagonists.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76936/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Abatacept, Upadacitinib, Siponimod, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76836, 'Encorafenib', 'Cyclosporine', 'Moderate', 'Coadministration with encorafenib may alter the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4, resulting in increased toxicity or decreased efficacy of these drugs.', 'DDInter', 'Concomitant use of encorafenib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided. These drugs include, but are not limited to: alfentanil, cisapride, colchicine, cyclosporine, fentanyl, ivacaftor, lovastatin, simvastatin, oral midazolam, triazolam, pimozide, quinidine, sildenafil, ergot derivatives, macrolide immunosuppressants, and vinca alkaloids.', 'Metabolism', 'Concomitant use of encorafenib and sensitive CYP450 3A4 substrates or substrates with narrow therapeutic ranges should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76937/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76837, 'Entecavir', 'Cyclosporine', 'Moderate', 'Because entecavir is primarily eliminated by renal excretion, coadministration with drugs that affect renal function may alter the plasma concentrations of entecavir and/or the coadministered drug. In patients with renal impairment, the apparent oral clearance of entecavir has been shown to decrease as the creatinine clearance decreases.', 'DDInter', 'Caution is advised if entecavir is prescribed in combination with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Renal function should be evaluated prior to and during therapy with entecavir.', 'Excretion', 'Caution is advised if entecavir is prescribed in combination with potentially nephrotoxic drugs (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76938/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More', 'Cabotegravir, Zanamivir, Velpatasvir, Stavudine, Elbasvir, Tecovirimat, Pibrentasvir, Rimantadine, Elvitegravir, Peramivir, Emtricitabine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76838, 'Entrectinib', 'Cyclosporine', 'Moderate', 'Coadministration with entrectinib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 3A4 by entrectinib. The interaction may be particularly important for sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index.', 'DDInter', 'Caution may be advisable when entrectinib is used with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, lovastatin, macrolide immunosuppressants, midazolam, sildenafil, simvastatin, triazolam, vardenafil, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever entrectinib is added to or withdrawn from therapy.', 'Metabolism', 'Caution may be advisable when entrectinib is used with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76939/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76839, 'Enzalutamide', 'Cyclosporine', 'Moderate', 'Coadministration with inhibitors of CYP450 2C8 and/or 3A4 may increase the plasma concentrations of enzalutamide, which is primarily metabolized by CYP450 2C8 to its pharmacologically active metabolite, N-desmethyl enzalutamide, and to a lesser extent by CYP450 3A4.', 'DDInter', 'Pharmacologic response to enzalutamide should be monitored more closely whenever a CYP450 2C8 and/or 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary. Patients should be advised to contact their physician if they experience increased side effects such as seizure, asthenia, fatigue, diarrhea, arthralgia, musculoskeletal pain, paresthesia, hot flushes, peripheral edema, headache, dizziness, insomnia, hematuria, anxiety, and hypertension.', 'Metabolism', 'Pharmacologic response to enzalutamide should be monitored more closely whenever a CYP450 2C8 and/or 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76940/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 'Darolutamide, Anastrozole, Letrozole, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide, Abiraterone, Exemestane', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76840, 'Eplerenone', 'Cyclosporine', 'Moderate', 'Cyclosporine may cause hyperkalemia. The concurrent use of potassium-sparing diuretics and cyclosporine may result in or exacerbate hyperkalemia.', 'DDInter', 'The concomitant use of potassium-sparing diuretics and cyclosporine should be avoided. A different class of antihypertensive should be considered.', 'Synergism', 'The concomitant use of potassium-sparing diuretics and cyclosporine should be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76941/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76841, 'Erythropoietin', 'Cyclosporine', 'Moderate', 'Concomitant use of cyclosporine with erythropoiesis-stimulating agents (ESAs) may produce additive increases on blood pressure. Either treatment alone may commonly cause hypertension, which can be severe or difficult to control in some cases. Additionally, use of ESAs may alter cyclosporine blood levels, since cyclosporine is bound by red blood cells.', 'DDInter', 'Caution is advised if cyclosporine is prescribed in combination with ESAs. Blood pressure should be adequately controlled before initiating treatment and monitored periodically during treatment. Patients who develop hypertension that is difficult to control by medications or dietary measures should have their ESA treatment reduced or withheld. In addition, cyclosporine blood levels should be checked regularly, as changes may occur following the addition, withdrawal, or change of dosage of ESA therapy. Dosage adjustments for cyclosporine may be required with increases in hematocrit levels.', 'Synergism', 'Caution is advised if cyclosporine is prescribed in combination with ESAs.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76942/', '', 'Luspatercept, Daprodustat', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76842, 'Eprosartan', 'Cyclosporine', 'Moderate', 'Coadministration of cyclosporine with ACE inhibitors or angiotensin II receptor antagonists may increase the risk of hyperkalemia or precipitate acute renal failure. Cyclosporine causes afferent arteriolar vasoconstriction and decreased glomerular filtration. These effects may be significant when combined with ACE inhibitors or angiotensin II receptor antagonists, which block the mechanism that maintains glomerular filtration rate by constricting the efferent arterioles.', 'DDInter', 'Serum potassium levels and renal function should be checked regularly when cyclosporine is used in combination with ACE inhibitors or angiotensin II receptor antagonists. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.', 'Excretion', 'Serum potassium levels and renal function should be checked regularly when cyclosporine is used in combination with ACE inhibitors or angiotensin II receptor antagonists.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76943/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, More', 'Nebivolol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76843, 'Erdafitinib', 'Cyclosporine', 'Moderate', 'Coadministration with erdafitinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter, resulting in increased toxicity of these drugs. In vitro, erdafitinib has been shown to be an inhibitor of P-gp.', 'DDInter', 'Concomitant use of erdafitinib and P-gp substrates should generally be avoided. If concomitant use is required, administer erdafitinib at least 6 hours before or after administration of P-gp substrates with narrow therapeutic ranges.', 'Distribution', 'Concomitant use of erdafitinib and P-gp substrates should generally be avoided.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76944/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 'Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76844, 'Ergometrine', 'Cyclosporine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors.', 'DDInter', 'Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors. Patients should be monitored for potential ergot toxicity including peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension.', 'Metabolism', 'Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76945/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 'Dinoprostone, Oxytocin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76845, 'Ergotamine', 'Cyclosporine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. The interaction has occurred in patients receiving ergotamine or dihydroergotamine with potent CYP450 3A4 inhibitors such as macrolide antibiotics and protease inhibitors.', 'DDInter', 'Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors. Patients should be monitored for potential ergot toxicity including peripheral vasospasm, ischemia, thrombosis, tachycardia, and hypertension.', 'Metabolism', 'Caution is advised during concomitant use of ergot derivatives with mild or moderate CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76946/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 'Frovatriptan, Eptinezumab, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Erenumab, Almotriptan, Fremanezumab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76846, 'Eribulin', 'Cyclosporine', 'Minor', 'The concomitant use of eribulin with drugs that inhibit hepatic transport proteins (e.g., organic anion-transporting proteins or multidrug resistant proteins) may theoretically increase its plasma concentrations. Up to 70% of an eribulin dose is eliminated through biliary excretion. Clinical data have not been reported.', 'DDInter', '-', 'Excretion', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76947/', '', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Porfimer sodium, Selinexor, Aflibercept, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76847, 'Erythromycin', 'Cyclosporine', 'Major', 'Coadministration with macrolide antibiotics that are potent inhibitors of CYP450 3A4 may significantly increase the blood concentrations of cyclosporine, which is primarily metabolized by the isoenzyme. The risk of nephro- and neurotoxicity associated with cyclosporine may be increased. Macrolides that may significantly inhibit CYP450 3A4 include troleandomycin, erythromycin, and clarithromycin.', 'DDInter', 'Caution is advised if cyclosporine is used with macrolide antibiotics that are potent inhibitors of CYP450 3A4. Cyclosporine blood levels and renal function should be checked frequently and the dosage adjusted accordingly, particularly following initiation or discontinuation of macrolide therapy in patients who are stabilized on their cyclosporine regimen. Patients should be advised to notify their doctor if they experience possible signs of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions. Alternative antibiotics that do not interfere with cyclosporine metabolism should be considered whenever possible.', 'Metabolism', 'Caution is advised if cyclosporine is used with macrolide antibiotics that are potent inhibitors of CYP450 3A4.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76948/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Anakinra, More', 'Lincomycin, Dirithromycin, Vitamin A, Azelaic acid, Adapalene, Isotretinoin, Rifamycin, Oxytetracycline, Lomefloxacin, Trifluridine, Benzylpenicillin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76848, 'Escitalopram', 'Cyclosporine', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 is not expected to significantly affect the pharmacokinetics of citalopram or escitalopram, both of which are partially metabolized by the isoenzyme. Administration of racemic citalopram (40 mg) in combination with the potent CYP450 3A4 inhibitor ketoconazole (200 mg) decreased the ketoconazole peak plasma concentration (Cmax) by 21% and systemic exposure (AUC) by 10%, but did not significantly affect the pharmacokinetics of citalopram.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76949/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 'Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, Phenelzine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76849, 'Esomeprazole', 'Cyclosporine', 'Moderate', 'Chronic use of proton pump inhibitors (PPIs) may induce hypomagnesemia, and the risk may be increased during concomitant use of diuretics or other agents that can cause magnesium loss. Serious adverse events include tetany, seizures, tremor, carpopedal spasm, atrial fibrillation, supraventricular tachycardia, and abnormal QT interval; however, patients do not always exhibit these symptoms. Hypomagnesemia can also cause impaired parathyroid hormone secretion, which may lead to hypocalcemia. In approximately 25% of the cases of PPI-associated hypomagnesemia reviewed by the FDA, the condition did not resolve with magnesium supplementation alone but also required discontinuation of the PPI.', 'DDInter', 'Monitoring of serum magnesium levels is recommended prior to initiation of therapy and periodically thereafter if prolonged treatment with a proton pump inhibitor is anticipated or when combined with other agents that can cause hypomagnesemia such as diuretics, aminoglycosides, cation exchange resins, amphotericin B, cetuximab, cisplatin, cyclosporine, foscarnet, panitumumab, pentamidine, and tacrolimus. Patients should be advised to seek immediate medical attention if they develop potential signs and symptoms of hypomagnesemia such as palpitations, arrhythmia, muscle spasm, tremor, or convulsions. In children, abnormal heart rates may cause fatigue, upset stomach, dizziness, and lightheadedness. Magnesium replacement as well as discontinuation of the PPI may be required in some patients.', 'Synergism', 'Monitoring of serum magnesium levels is recommended prior to initiation of therapy and periodically thereafter if prolonged treatment with a proton pump inhibitor is anticipated or when combined with other agents that can cause hypomagnesemia such as diuretics, aminoglycosides, cation exchange resins, amphotericin B, cetuximab, cisplatin, cyclosporine, foscarnet, panitumumab, pentamidine, and tacrolimus.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76950/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Upadacitinib, More', 'Vonoprazan, Bismuth subcitrate potassium, Levofloxacin, Chondroitin sulfate, Glucosamine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76850, 'Etanercept', 'Cyclosporine', 'Major', 'The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).', 'DDInter', 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.', 'Synergism', 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76951/', '', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Etanercept, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Alteplase, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76851, 'Ethotoin', 'Cyclosporine', 'Moderate', 'Phenytoin may significantly reduce cyclosporine serum concentrations. The mechanism may be inhibition of cyclosporine absorption or induction of hepatic CYP450 metabolism or both. This interaction may occur with ethotoin, fosphenytoin, and mephenytoin as well.', 'DDInter', 'Cyclosporine levels should be closely monitored during concomitant therapy and more frequently when phenytoin is started or stopped. The dosage of cyclosporine should be adjusted to maintain therapeutic concentrations. Some experts suggest that this interaction could persist for a week or more following discontinuation of phenytoin.', 'Metabolism', 'Cyclosporine levels should be closely monitored during concomitant therapy and more frequently when phenytoin is started or stopped.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76952/', '', 'Golimumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Tacrolimus, Abatacept, Upadacitinib, More', 'Tiagabine, Brivaracetam, Methsuximide, Ezogabine, Cenobamate, Paramethadione, Perampanel, Fenfluramine, Eslicarbazepine, Phensuximide, Phenacemide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76852, 'Etidronic acid', 'Cyclosporine', 'Moderate', 'Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure.', 'DDInter', 'Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents). Renal function and serum electrolytes should be monitored. Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.', 'Synergism', 'Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76953/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Tiludronic acid, Vosoritide, Cholecalciferol, Burosumab, Romosozumab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76853, 'Etodolac', 'Cyclosporine', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the nephrotoxic effects of cyclosporine, especially if dehydration is present. The exact mechanism is unknown but is apparently unrelated to plasma cyclosporine levels. The interaction has been reported with diclofenac and sulindac.', 'DDInter', 'Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76954/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Chondroitin sulfate, Glucosamine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76854, 'Etonogestrel', 'Cyclosporine', 'Moderate', 'Coadministration with some estrogens or progestins may increase the plasma concentrations of cyclosporine. The risk of cyclosporine-induced nephrotoxicity, hepatotoxicity, and neurotoxicity may be increased. The proposed mechanism is competitive inhibition of cyclosporine metabolism via CYP450 3A4, of which estrogens and progestins are also substrates.', 'DDInter', 'Caution is advised during concomitant therapy with cyclosporine. Cyclosporine blood levels as well as renal and hepatic function should be checked frequently and the dosage adjusted accordingly, particularly following initiation or discontinuation of hormonal contraceptives in patients who are stabilized on their cyclosporine regimen. Patients should be advised to notify their physician if they experience signs and symptoms of hepatotoxicity (e.g., fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, jaundice) or neurotoxicity (e.g., tremor, convulsions).', 'Metabolism', 'Caution is advised during concomitant therapy with cyclosporine.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76955/', '', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Methotrexate, Abatacept, Upadacitinib, Siponimod, Apremilast, Inebilizumab, Belumosudil, More', 'Estetrol', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76855, 'Etoposide', 'Cyclosporine', 'Moderate', 'High-dose cyclosporine (concentration greater than 2,000 ng/mL) has been shown to significantly increase systemic etoposide exposure and leukopenia. The mechanism is believed to be inhibition of the multidrug transporter P-glycoprotein in normal tissues.', 'DDInter', 'In combination with high-dose cyclosporine, etoposide dosage may be reduced by 50%. Complete blood counts should be monitored.', 'Distribution', 'In combination with high-dose cyclosporine, etoposide dosage may be reduced by 50%.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76956/', '', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, More', 'Topotecan, Teniposide, Vinorelbine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76856, 'Etravirine', 'Cyclosporine', 'Moderate', 'Coadministration of etravirine with a drug that is both a substrate as well as inhibitor of CYP450 3A4 may result in increased plasma concentrations of etravirine and decreased plasma concentrations of the other drug. Etravirine itself is a substrate and inducer of CYP450 3A4. Theoretically, etravirine may induce metabolism of the coadministered drug while its own metabolism may be inhibited by the coadministered drug.', 'DDInter', 'Because safety data regarding increased etravirine exposures are limited, caution is advised if etravirine is prescribed in combination with a drug that is an inhibitor of CYP450 3A4. In addition, dosage adjustments may be required for the coadministered drug if it is also a substrate of CYP450 3A4.', 'Metabolism', 'Because safety data regarding increased etravirine exposures are limited, caution is advised if etravirine is prescribed in combination with a drug that is an inhibitor of CYP450 3A4.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76957/', '', 'Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Abatacept, Anakinra, More', 'Cabotegravir, Zanamivir, Velpatasvir, Stavudine, Elbasvir, Tecovirimat, Pibrentasvir, Rimantadine, Elvitegravir, Peramivir, Emtricitabine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76857, 'Everolimus', 'Cyclosporine', 'Major', 'Coadministration with cyclosporine may significantly increase the plasma concentrations of everolimus. The mechanism is cyclosporine inhibition of the CYP450 3A4 first-pass metabolism and intestinal P-glycoprotein secretion of everolimus.', 'DDInter', 'Everolimus should generally not be used with potent or moderate inhibitors of CYP450 3A4 and/or P-glycoprotein. The possibility of prolonged and/or increased pharmacologic effects of everolimus therapy should be considered in patients who require coadministration with cyclosporine, including adverse effects such as pneumonitis, stomatitis, infection, dyspnea, diarrhea, anemia, leucopenia, thrombocytopenia, hyperglycemia, and hyperlipidemia. Therapeutic drug monitoring is recommended whenever cyclosporine is added to or withdrawn from therapy, and the dosage(s) of one or both drugs adjusted as necessary. Renal function tests including serum creatinine and blood urea nitrogen (BUN) should also be performed regularly during coadministration.', 'Metabolism, Absorption', 'Everolimus should generally not be used with potent or moderate inhibitors of CYP450 3A4 and/or P-glycoprotein.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76958/', '', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Mycophenolic acid, Tacrolimus, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, More', 'Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76858, 'Exenatide', 'Cyclosporine', 'Moderate', 'Drugs that affect renal function and/or hydration status may potentiate the adverse renal effects of exenatide. The mechanism of interaction is unknown. Exenatide has not been found to be directly nephrotoxic in preclinical or clinical studies.', 'DDInter', 'Clinicians should be aware of the potential for increased adverse renal effects of exenatide during coadministration with drugs that are known to affect renal function or hydration status.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76959/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Alogliptin, Liraglutide, Ertugliflozin, Semaglutide, Linagliptin, Nateglinide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76859, 'Fedratinib', 'Cyclosporine', 'Moderate', 'Coadministration of fedratinib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4, 2C19, or 2D6 isoenzymes.', 'DDInter', 'Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, or 2D6. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fedratinib is added to or withdrawn from therapy, particularly those with a narrow therapeutic index.', 'Metabolism', 'Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, or 2D6.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76960/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76860, 'Felodipine', 'Cyclosporine', 'Moderate', 'Cyclosporine may significantly increase serum felodipine concentrations by inhibition of CYP450 3A4 first pass metabolism. The clinical significance of increased felodipine levels appears negligible in healthy volunteers. Felodipine may also increase cyclosporine concentrations but to a lesser extent. Serum cyclosporine concentrations and the risk of cyclosporine-induced neurotoxicity and nephrotoxicity may be increased.', 'DDInter', 'Clinical and laboratory monitoring for altered efficacy and safety (e.g., increased cyclosporine levels, excessive hypotension, or nephrotoxicity) of both drugs is recommended during concomitant therapy and when the dose of either drug is changed or discontinued. Dosage adjustments may be required. Amlodipine undergoes less first-pass metabolism and may be considered as an alternative. Patients should be advised to notify their physician if they experience nausea, vomiting, diarrhea, abdominal pain, dizziness, syncope, fatigue, or headache.', 'Metabolism, Synergism', 'Clinical and laboratory monitoring for altered efficacy and safety (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76961/', '', 'Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, Apremilast, Inebilizumab, Cladribine, Belumosudil, Belimumab, More', 'Nebivolol, Clevidipine, Nimodipine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76861, 'Fenofibric acid', 'Cyclosporine', 'Moderate', 'The concomitant use of cyclosporine and fibric acid derivatives may increase the risk of nephrotoxicity. Fibrates are primarily eliminated by the kidneys and increases in serum creatinine and/or cyclosporine levels may occur.', 'DDInter', 'The manufacturer recommends caution during concomitant administration. Renal function should be closely monitored and the lowest effective dose should be used.', 'Excretion', 'The manufacturer recommends caution during concomitant administration.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76962/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More', 'Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Colestipol, Bempedoic acid, Alirocumab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76862, 'Fenoldopam', 'Cyclosporine', 'Minor', 'Limited data have shown that fenoldopam can improve renal function in patients with decreased renal function associated with the use of cyclosporine. (Cyclosporine causes renal vasoconstriction and reduced renal blood flow that may contribute to chronic nephrotoxicity.) The mechanism by which fenoldopam increases urine flow rate, fractional excretion of sodium, effective renal plasma flow, and glomerular filtration rate is probably related to its renal vasodilating abilities. This combination can be used to advantage.', 'DDInter', '-', 'Metabolism, Excretion', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76963/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Metaraminol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76863, 'Fenoprofen', 'Cyclosporine', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the nephrotoxic effects of cyclosporine, especially if dehydration is present. The exact mechanism is unknown but is apparently unrelated to plasma cyclosporine levels. The interaction has been reported with diclofenac and sulindac.', 'DDInter', 'Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76964/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Chondroitin sulfate, Glucosamine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76864, 'Fesoterodine', 'Cyclosporine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of fesoterodine''s active metabolite, 5-hydroxymethyl tolterodine, which is partially metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of fesoterodine should be considered. Because 5-hydroxymethyl tolterodine is also metabolized by CYP450 2D6, the clinical significance of the interaction may be greater in patients who are CYP450 2D6-deficient, or so-called poor metabolizers of CYP450 2D6 (approximately 7% of Caucasians and less than 2% of Asians and individuals of African descent) who may rely more on the 3A4 metabolic pathway for clearance of the drug.', 'DDInter', 'Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from fesoterodine therapy, and the dosage adjusted if necessary. Patients should be advised to notify their physician if they experience potential adverse effects of fesoterodine such as irregular heartbeat, blurry vision, difficulty urinating, dry mouth, headache, drowsiness, dizziness, gastrointestinal upset, or constipation.', 'Metabolism', 'Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from fesoterodine therapy, and the dosage adjusted if necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76965/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 'Apomorphine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Avanafil, Papaverine, Magnesium hydroxide, Ammonium chloride, Dimethyl sulfoxide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76865, 'Fidaxomicin', 'Cyclosporine', 'Minor', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of fidaxomicin and its main metabolite, OP-1118, both of which are substrates of the intestinal efflux transporter. Theoretically, concentrations of fidaxomicin and OP-1118 may also be decreased at the site of action (i.e., gastrointestinal tract) due to P-gp inhibition.', 'DDInter', '-', 'Absorption', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76966/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 'Rifamycin, Paromomycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76866, 'Fingolimod', 'Cyclosporine', 'Major', 'Coadministration of fingolimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of infections. Fingolimod causes reversible sequestration of lymphocytes in lymphoid tissues.', 'DDInter', 'The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration. A complete blood count is recommended prior to starting fingolimod if a recent one (i.e., within last 6 months) is not available.', 'Synergism', 'The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76967/', '', 'Pegcetacoplan, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Fingolimod, Eculizumab, Sutimlimab, Alteplase, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76867, 'Flibanserin', 'Cyclosporine', 'Moderate', 'Coadministration with flibanserin may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter.', 'DDInter', 'Caution is advised when flibanserin is prescribed with drugs that are P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever flibanserin is added to or withdrawn from therapy.', 'Others', 'Caution is advised when flibanserin is prescribed with drugs that are P-gp substrates, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76968/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 'Ritodrine, Bremelanotide, Cabergoline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76868, 'Fluconazole', 'Cyclosporine', 'Moderate', 'Fluconazole may inhibit the CYP450 3A4 hepatic and/or gut wall metabolism of cyclosporine. Serum cyclosporine concentrations and risk of toxicity may be increased, although the data are conflicting. This interaction may be more likely with higher doses of fluconazole (more than 200 mg per day).', 'DDInter', 'If concomitant therapy is necessary, serum cyclosporine levels and renal function should be closely monitored. Dosage adjustments may be required. Patients should be advised to notify their physician if they experience nausea, vomiting, diarrhea, abdominal pain, fatigue, or headache.', 'Metabolism', 'If concomitant therapy is necessary, serum cyclosporine levels and renal function should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76969/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Anakinra, More', 'Cefixime, Levofloxacin, Secnidazole, Micafungin, Oteseconazole, Selenium Sulfide, Thiabendazole, Econazole, Tioconazole, Chlorphenesin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76869, 'Flucytosine', 'Cyclosporine', 'Moderate', 'Drugs that impair glomerular filtration may prolong the half-life of flucytosine and lead to accumulation.', 'DDInter', 'Caution is advised if flucytosine is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).', 'Excretion', 'Caution is advised if flucytosine is used in patients who have recently received or are receiving treatment with potentially nephrotoxic drugs (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76970/', '', 'Golimumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, More', 'Micafungin, Oteseconazole, Selenium Sulfide, Thiabendazole, Econazole, Tioconazole, Chlorphenesin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76870, 'Fludrocortisone', 'Cyclosporine', 'Moderate', 'Coadministration of cyclosporine with a corticosteroid may result in altered (usually elevated) plasma concentrations of one or both drugs. Cyclosporine and corticosteroids undergo metabolism primarily by CYP450 3A4, thus competitive inhibition of metabolic clearance may occur during concomitant use.', 'DDInter', 'Caution is advised during concomitant therapy with cyclosporine and corticosteroids. Pharmacologic responses and/or plasma drug levels should be monitored more closely whenever one or the other agent is added to or withdrawn from therapy in patients stabilized on their existing therapeutic regimen, and the dosage(s) adjusted as necessary.', 'Metabolism', 'Caution is advised during concomitant therapy with cyclosporine and corticosteroids.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76971/', '', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More', 'Fluocinolone acetonide, Fluocinolone acetonide', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76871, 'Fluoxetine', 'Cyclosporine', 'Moderate', 'A case report has suggested that the addition or discontinuation of fluoxetine may increase or decrease cyclosporine levels, respectively. The proposed mechanism is inhibition of CYP450 3A4 hepatic microsomal enzymes.', 'DDInter', 'Until more information is available, cyclosporine levels and renal function, including serum creatinine, should be carefully monitored. Patients should be advised to notify their physician if they experience nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, or headache.', 'Metabolism', 'Until more information is available, cyclosporine levels and renal function, including serum creatinine, should be carefully monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76972/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Amitriptyline, Maprotiline, Vortioxetine, Milnacipran, Levomilnacipran, Doxepin, Isocarboxazid, Viloxazine, Amoxapine, Imipramine, Esketamine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76872, 'Fluoxymesterone', 'Cyclosporine', 'Moderate', 'Coadministration with androgens or anabolic steroids may increase the blood concentrations of cyclosporine. The exact mechanism of interaction is unknown but may involve competitive inhibition of the CYP450 3A4 metabolism of cyclosporine.', 'DDInter', 'Caution is advised if cyclosporine is prescribed with androgens or anabolic steroids. Cyclosporine blood levels, renal function, and liver function tests should be monitored frequently and the dosage adjusted accordingly, particularly following initiation, discontinuation or change of androgen dosage in patients who are stabilized on their cyclosporine regimen. Patients should be advised to notify their physician if they experience possible signs of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions.', 'Metabolism', 'Caution is advised if cyclosporine is prescribed with androgens or anabolic steroids.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76973/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76873, 'Flurbiprofen', 'Cyclosporine', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the nephrotoxic effects of cyclosporine, especially if dehydration is present. The exact mechanism is unknown but is apparently unrelated to plasma cyclosporine levels. The interaction has been reported with diclofenac and sulindac.', 'DDInter', 'Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76974/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Tolazoline, Dimethyl sulfoxide, Chondroitin sulfate, Glucosamine, Chlorhexidine, Povidone-iodine, Fluocinolone acetonide, Bromfenac', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76874, 'Fluvastatin', 'Cyclosporine', 'Moderate', 'Coadministration with cyclosporine may moderately increase the plasma concentrations of fluvastatin. The proposed mechanism is cyclosporine inhibition of the hepatic cytochrome P450 isoenzyme responsible for the metabolic clearance of fluvastatin, possibly CYP450 3A4.', 'DDInter', 'Patients should be monitored for development of adverse effects including myopathy. Some authorities recommend that the dose of fluvastatin should not exceed 20 mg twice daily when coadministered with cyclosporine. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.', 'Metabolism', 'Patients should be monitored for development of adverse effects including myopathy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76975/', '', 'Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, Abatacept, Upadacitinib, More', 'Evinacumab, Evolocumab, Dextrothyroxine, Cholestyramine, Colestipol, Bempedoic acid, Alirocumab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76875, 'Gentamicin', 'Cyclosporine', 'Moderate', 'The nephrotoxic effects of cyclosporine and aminoglycosides are additive. The combination generally should be avoided.', 'DDInter', 'If these agents must be used concomitantly, renal function should be closely monitored.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76976/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More', 'Rifamycin, Oxytetracycline, Lomefloxacin, Trifluridine, Benzylpenicillin, Ampicillin, Chlorhexidine, Levofloxacin, Povidone-iodine, Rifamycin, Chlorhexidine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76876, 'Givosiran', 'Cyclosporine', 'Moderate', 'The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.', 'DDInter', 'Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.', 'Synergism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76977/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Levocarnitine, Laronidase, Imiglucerase, Phenylbutyric acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76877, 'Glasdegib', 'Cyclosporine', 'Moderate', 'Coadministration with glasdegib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) efflux transporters.', 'DDInter', 'Caution is advised if glasdegib is coadministered with drugs that are substrates of P-gp and/or BCRP, particularly those with a narrow therapeutic range. Clinical and laboratory monitoring should be considered whenever glasdegib is added to or withdrawn from therapy with these drugs, and dosages adjusted as necessary. Patients should be monitored for the development of adverse effects.', 'Absorption', 'Caution is advised if glasdegib is coadministered with drugs that are substrates of P-gp and/or BCRP, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76978/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Pertuzumab, Tisagenlecleucel, Aminolevulinic acid, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Porfimer sodium, Selinexor, Aflibercept, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76878, 'Glimepiride', 'Cyclosporine', 'Moderate', 'Glipizide may decrease the metabolism of cyclosporine. Cyclosporine levels may be increased by as much as 150%. It is not known whether other sulfonylureas will exhibit a similar interaction, although limited data do exist for glyburide. The proposed mechanism is inhibition of CYP450 hepatic metabolism.', 'DDInter', 'If a sulfonylurea is added or discontinued in a patient stabilized on cyclosporine, serum cyclosporine levels should be closely monitored. Patients should be advised to notify their physician if they experience nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, or headache.', 'Metabolism', 'If a sulfonylurea is added or discontinued in a patient stabilized on cyclosporine, serum cyclosporine levels should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76979/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Alogliptin, Liraglutide, Ertugliflozin, Semaglutide, Linagliptin, Nateglinide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76879, 'Glipizide', 'Cyclosporine', 'Moderate', 'Glipizide may decrease the metabolism of cyclosporine. Cyclosporine levels may be increased by as much as 150%. It is not known whether other sulfonylureas will exhibit a similar interaction, although limited data do exist for glyburide. The proposed mechanism is inhibition of CYP450 hepatic metabolism.', 'DDInter', 'If a sulfonylurea is added or discontinued in a patient stabilized on cyclosporine, serum cyclosporine levels should be closely monitored. Patients should be advised to notify their physician if they experience nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, or headache.', 'Metabolism', 'If a sulfonylurea is added or discontinued in a patient stabilized on cyclosporine, serum cyclosporine levels should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76980/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Alogliptin, Liraglutide, Ertugliflozin, Semaglutide, Linagliptin, Nateglinide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76880, 'Glyburide', 'Cyclosporine', 'Moderate', 'Glipizide may decrease the metabolism of cyclosporine. Cyclosporine levels may be increased by as much as 150%. It is not known whether other sulfonylureas will exhibit a similar interaction, although limited data do exist for glyburide. The proposed mechanism is inhibition of CYP450 hepatic metabolism.', 'DDInter', 'If a sulfonylurea is added or discontinued in a patient stabilized on cyclosporine, serum cyclosporine levels should be closely monitored. Patients should be advised to notify their physician if they experience nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, or headache.', 'Metabolism', 'If a sulfonylurea is added or discontinued in a patient stabilized on cyclosporine, serum cyclosporine levels should be closely monitored.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76981/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Alogliptin, Liraglutide, Ertugliflozin, Semaglutide, Linagliptin, Nateglinide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76881, 'Glycerol phenylbutyrate', 'Cyclosporine', 'Moderate', 'Coadministration with glycerol phenylbutyrate may decrease the systemic exposure to and therapeutic efficacy of drugs that are substrates of CYP450 3A4. Glycerol phenylbutyrate, its active moiety phenylbutyrate, and active metabolite phenylacetic acid are considered weak CYP450 3A4 inducers in vivo.', 'DDInter', 'Concomitant use of glycerol phenylbutyrate with sensitive CYP450 3A4 substrates (e.g., oral midazolam) or CYP450 3A4 substrates with a narrow therapeutic index (e.g., alfentanil, oral contraceptives, quinidine, and cyclosporine) should be done with caution and monitoring for reduced efficacy. Dosage adjustment as well as clinical and laboratory monitoring may be appropriate whenever glycerol phenylbutyrate is added to or withdrawn from therapy.', 'Metabolism', 'Concomitant use of glycerol phenylbutyrate with sensitive CYP450 3A4 substrates (e.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76982/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 'Lipoic acid, Triheptanoin, Teduglutide, Fosdenopterin, Triethylenetetramine, Miglustat, Sapropterin, Levocarnitine, Laronidase, Imiglucerase, Phenylbutyric acid, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76882, 'Golimumab', 'Cyclosporine', 'Major', 'The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).', 'DDInter', 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.', 'Synergism', 'Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76983/', '', 'Golimumab, Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Alteplase, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76883, 'Grepafloxacin', 'Cyclosporine', 'Moderate', 'Based on in vitro inhibition data, coadministration with grepafloxacin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by grepafloxacin.', 'DDInter', 'Caution is advised if grepafloxacin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever grepafloxacin is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised if grepafloxacin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76984/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More', 'Enoxacin, Levofloxacin, Nalidixic acid, Gemifloxacin, Lomefloxacin, Cinoxacin, Trovafloxacin, Delafloxacin, Sparfloxacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76884, 'Griseofulvin', 'Cyclosporine', 'Moderate', 'Griseofulvin may decrease serum cyclosporine concentrations by an unknown mechanism. Loss of efficacy may occur.', 'DDInter', 'Monitoring of cyclosporine levels during concomitant administration is recommended, as is close observation of the patient for signs of rejection or toxicity when griseofulvin is added to or discontinued from therapy. Dose adjustments may be required.', 'Antagonism', 'Monitoring of cyclosporine levels during concomitant administration is recommended, as is close observation of the patient for signs of rejection or toxicity when griseofulvin is added to or discontinued from therapy.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76985/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 'Selenium Sulfide, Thiabendazole, Econazole, Tioconazole, Chlorphenesin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76885, 'Guanfacine', 'Cyclosporine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of guanfacine, which is primarily metabolized by the isoenzyme.', 'DDInter', 'Caution is advised when guanfacine is used with CYP450 3A4 inhibitors. Patients should be monitored for increased adverse effects such as hypotension, bradycardia and sedation , and the guanfacine dosage adjusted as necessary.', 'Metabolism', 'Caution is advised when guanfacine is used with CYP450 3A4 inhibitors.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76986/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 'Rauwolfia serpentina root, Reserpine, Deserpidine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76886, 'Guselkumab', 'Cyclosporine', 'Moderate', 'The use of interleukin blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Plasma concentrations of drugs that are CYP450 substrates may decrease following the initiation of interleukin inhibitors in patients with chronic inflammatory diseases.', 'DDInter', 'Concomitant use of interleukin blockers with other immuno- or myelosuppressive agents should be avoided if possible. Caution is advised when interleukin inhibitors are prescribed to patients receiving concomitant drugs that are CYP450 substrates, particularly those with narrow therapeutic ranges such as immunosuppressants or antineoplastic agents. Clinical and/or laboratory monitoring should be considered following the initiation or withdrawal of interleukin inhibitor therapy, and the dosage(s) of these drugs adjusted accordingly. Clinicians should note that the effects of interleukin inhibitors on CYP450 activities may persist for several weeks after stopping therapy.', 'Metabolism', 'Concomitant use of interleukin blockers with other immuno- or myelosuppressive agents should be avoided if possible.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76987/', '', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More', 'Cyclosporine, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Ravulizumab, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, Emapalumab, Sutimlimab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76887, 'Halofantrine', 'Cyclosporine', 'Major', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of halofantrine, resulting in an increased risk of QT interval prolongation and ventricular arrhythmias. The mechanism is inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of halofantrine. Halofantrine has been associated with QT interval prolongation, ventricular arrhythmias, and sudden death, even at recommended dosages.', 'DDInter', 'Caution and close monitoring is recommended if halofantrine is prescribed with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors. The manufacturer recommends performing an ECG before initiating halofantrine therapy and cardiac monitoring during and for 8 to 12 hours after completion of therapy.', 'Metabolism', 'Caution and close monitoring is recommended if halofantrine is prescribed with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76988/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 'Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Primaquine, Proguanil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76888, 'Hepatitis A Vaccine', 'Cyclosporine', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', 'DDInter', 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76989/', '', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Alteplase, Ascorbic acid, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76889, 'Hepatitis B Vaccine (Recombinant)', 'Cyclosporine', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', 'DDInter', 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76990/', '', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Alteplase, Ascorbic acid, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76890, 'Human papillomavirus type 11 L1 capsid protein antigen', 'Cyclosporine', 'Moderate', 'The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.', 'DDInter', 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin''s disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.', 'Antagonism', 'In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76991/', '', 'Apremilast, Pirfenidone, Belumosudil, Teprotumumab, Emapalumab, Ravulizumab, Pegcetacoplan, Eculizumab, Sutimlimab, Alteplase, Ascorbic acid, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76891, 'Hydroflumethiazide', 'Cyclosporine', 'Moderate', 'Coadministration of thiazide or thiazide-like diuretics with cyclosporine may potentially result in hypermagnesemia, hyperuricemia, and increase the risk of nephrotoxicity.', 'DDInter', 'Monitoring of renal function, serum electrolytes, uric acid levels, and cyclosporine blood concentrations is advisable during concomitant use. Some authorities advise against concomitant use of these medicines.', 'Others', 'Monitoring of renal function, serum electrolytes, uric acid levels, and cyclosporine blood concentrations is advisable during concomitant use.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76992/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More', 'Trichlormethiazide, Methyclothiazide, Ascorbic acid, Methazolamide, Oxytetracycline, Trichlormethiazide, Diazoxide, Econazole, Probenecid, Diclofenamide, Mafenide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76892, 'Hydroxychloroquine', 'Cyclosporine', 'Moderate', 'Coadministration with hydroxychloroquine or chloroquine may increase the plasma concentrations and risk of adverse effects of cyclosporine. The mechanism for this interaction has not been clearly delineated; however, it may involve hydroxychloroquine- or chloroquine-mediated inhibition of P-glycoprotein (P-gp), the enzyme at least partially responsible for the metabolism of cyclosporine.', 'DDInter', 'Caution is advised whenever chloroquine or hydroxychloroquine is used concomitantly with cyclosporine. Therapeutic drug monitoring of cyclosporine and monitoring of renal function is recommended whenever chloroquine or hydroxychloroquine is added to or withdrawn from therapy, and the cyclosporine dosage adjusted as necessary. Patients should be advised to notify their doctor if they experience possible signs of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions.', 'Metabolism', 'Caution is advised whenever chloroquine or hydroxychloroquine is used concomitantly with cyclosporine.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76993/', '', 'Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, Anakinra, More', 'Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Primaquine, Proguanil', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76893, 'Ibrutinib', 'Cyclosporine', 'Moderate', 'Coadministration with ibrutinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter. In vitro studies indicate that ibrutinib is not a substrate for P-gp, and systemic ibrutinib is unlikely to be an inhibitor of P-gp at clinical doses.', 'DDInter', 'Caution is advised if ibrutinib is prescribed in combination with orally administered P-gp substrates, particularly those with a narrow therapeutic range. Dosage reduction and/or dosage interval adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ibrutinib is added to or withdrawn from therapy. Some authorities recommend that narrow therapeutic range P-gp substrates, such as digoxin, should be administered at least 6 hours before or after ibrutinib.', 'Absorption', 'Caution is advised if ibrutinib is prescribed in combination with orally administered P-gp substrates, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76994/', '', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Ravulizumab, Mycophenolic acid, Methotrexate, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, More', 'Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76894, 'Idarubicin', 'Cyclosporine', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of daunorubicin and idarubicin, both of which are substrates of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor, in attempt to overcome multidrug resistance in MDR1-overexpressing tumors.', 'DDInter', 'Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.', 'Absorption', 'Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76995/', '', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Belimumab, More', 'Valrubicin, Plicamycin, Bleomycin, Mitomycin, Epirubicin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76895, 'Idelalisib', 'Cyclosporine', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the blood concentrations of cyclosporine, which is primarily metabolized by the isoenzyme. The risk of nephro- and neurotoxicity associated with cyclosporine may be increased.', 'DDInter', 'Caution is advised if cyclosporine is used with potent inhibitors of CYP450 3A4. Cyclosporine blood levels and renal function should be checked frequently and the dosage adjusted accordingly, particularly following initiation or discontinuation of macrolide therapy in patients who are stabilized on their cyclosporine regimen. Patients should be advised to notify their doctor if they experience possible signs of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions. Alternative treatment that do not interfere with cyclosporine metabolism should be considered whenever possible.', 'Metabolism', 'Caution is advised if cyclosporine is used with potent inhibitors of CYP450 3A4.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76996/', '', 'Antithymocyte immunoglobulin (rabbit), Secukinumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Thalidomide, Belimumab, Emapalumab, More', 'Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76896, 'Imatinib', 'Cyclosporine', 'Moderate', 'Coadministration with imatinib may increase the plasma concentrations of drugs that are substrates of CYP450 2C9, 2D6 and/or 3A4. The mechanism is decreased clearance due to inhibition of these isoenzymes by imatinib.', 'DDInter', 'Caution is advised when imatinib is used concomitantly with drugs that undergo metabolism by CYP450 2C9, 2D6 and/or 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever imatinib is added to or withdrawn from therapy.', 'Metabolism', 'Caution is advised when imatinib is used concomitantly with drugs that undergo metabolism by CYP450 2C9, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76997/', '', 'Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Anifrolumab, Ravulizumab, Mycophenolic acid, Abatacept, Apremilast, Inebilizumab, Belumosudil, Ozanimod, More', 'Sunitinib, Regorafenib, Midostaurin, Copanlisib, Lenvatinib, Erlotinib, Abemaciclib, Trametinib, Vandetanib, Dacomitinib, Tivozanib, Alectinib', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76897, 'Human immunoglobulin G (intravenous and subcutaneous)', 'Cyclosporine', 'Major', 'Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.', 'DDInter', 'Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.', 'Synergism', 'Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76998/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Diroximel fumarate, Mycophenolic acid, Abatacept, Upadacitinib, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76898, 'Indacaterol', 'Cyclosporine', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the systemic exposure to indacaterol following oral inhalation, as it is a substrate of both the isoenzyme and efflux transporter.', 'DDInter', '-', 'Metabolism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/76999/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 'Mometasone furoate, Terbutaline, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Olodaterol, Cromoglicic acid, Ipratropium, Orciprenaline, Pirbuterol, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76899, 'Indapamide', 'Cyclosporine', 'Moderate', 'Coadministration of thiazide or thiazide-like diuretics with cyclosporine may potentially result in hypermagnesemia, hyperuricemia, and increase the risk of nephrotoxicity.', 'DDInter', 'Monitoring of renal function, serum electrolytes, uric acid levels, and cyclosporine blood concentrations is advisable during concomitant use. Some authorities advise against concomitant use of these medicines.', 'Others', 'Monitoring of renal function, serum electrolytes, uric acid levels, and cyclosporine blood concentrations is advisable during concomitant use.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77000/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Tacrolimus, More', 'Ascorbic acid, Methazolamide, Oxytetracycline, Trichlormethiazide, Diazoxide, Econazole, Probenecid, Diclofenamide, Mafenide, Tioconazole, Furazolidone, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (76900, 'Indinavir', 'Cyclosporine', 'Major', 'Coadministration with protease inhibitors (PIs), especially ritonavir, may significantly increase the blood concentrations of cyclosporine. The risk of nephro- and neurotoxicity associated with cyclosporine may be increased. The mechanism involves PI inhibition of CYP450 3A4, the isoenzyme responsible for the intestinal and hepatic metabolism of cyclosporine. Enhanced cyclosporine oral bioavailability due to PI inhibition of intestinal P-glycoprotein efflux transporter may also contribute.', 'DDInter', 'Caution is advised if cyclosporine is used in combination with protease inhibitors. Cyclosporine blood levels and renal function should be checked frequently and the dosage adjusted accordingly, particularly following initiation or discontinuation of PI therapy in patients who are stabilized on their cyclosporine regimen. Patients should be advised to notify their physician if they experience possible signs of cyclosporine toxicity such as nausea, vomiting, diarrhea, abdominal pain, dizziness, fatigue, headache, tremors, and convulsions. Patients treated with saquinavir should also be monitored for potential PI toxicity and the dosage adjusted accordingly.', 'Metabolism, Absorption', 'Caution is advised if cyclosporine is used in combination with protease inhibitors.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/77001/', '', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, More', 'Cabotegravir, Zanamivir, Velpatasvir, Stavudine, Elbasvir, Tecovirimat, Pibrentasvir, Rimantadine, Elvitegravir, Peramivir, Emtricitabine, More', 1767369485);
